【摘要】目的:将利培酮与多奈哌齐用于老年痴呆精神行为症状治疗中,对患者PANSS评分变化及药物不良反应进行分析。方法:对我院收治的64例老年痴呆精神行为症状患者分组研究,以双盲法将其分成研究组(n=32)与参照组(n=32),参照组使用利培酮治疗,研究组在此基础上加入多奈哌齐治疗,对两组治疗结果进行比较。 结果:两组治疗前BEHAVE-AD评分相比,差异不显著(p>0.05),研究组治疗后2周、1个月、2个月BEHAVE-AD评分与参照组相比,相对更低(p<0.05);两组治疗前PANSS评分相比,差异不显著(p>0.05),研究组治疗后2周、1个月、2个月PANSS评分与参照组相比,相对更低(p<0.05);研究组总有效率为93.75%,与参照组75.00%相比,相对更高(p<0.05);研究组不良反应率为6.25%,与参照组15.63%相比,相对更高(p<0.05)。结论:对老年痴呆精神行为症状患者而言,使用利培酮与多奈哌齐联合治疗效果理想,可缓解患者精神行为症状,增强疗效,减少不良反应,值得应用。
【关键词】:利培酮;多奈哌齐;老年痴呆;精神行为症状
【Abstract】Objective: To use risperidone and donepezil in the treatment of mental behavior symptoms of Alzheimer's disease, and to analyze the changes of PANSS scores and adverse drug reactions. Methods: Sixty-four patients with mental behavior symptoms of Alzheimer's disease admitted to our hospital were divided into study group (n=32) and reference group (n=32) by double-blind method. The reference group was treated with risperidone. The group was treated with donepezil on the basis of this, and the treatment results of the two groups were compared. Results: There was no significant difference in BEHAVE-AD score between the two groups before treatment (p > 0.05). The BEHAVE-AD score in the study group was lower than that in the control group 2 weeks, 1 month and 2 months after treatment (p < 0.05); there was no significant difference in PANSS score between the two groups before treatment (p > 0.05). The PANSS score in the study group was lower than that in the control group 2 weeks, 1 month and 2 months after treatment (p < 0.05). The total effective rate of the study group was 93.75%, which was higher than that of the control group (75.00%, P < 0.05); the adverse reaction rate of the study group was 6.25%, which was higher than that of the control group (15.63%, P < 0.05). Conclusion : For senile dementia patients with psychobehavioral symptoms, the combination of risperidone and donepezil is ideal, which can alleviate psychobehavioral symptoms, enhance curative effect and reduce adverse reactions. It is worth applying.
[Key words] Risperidone; Donepezil; Alzheimer's disease; Psychobehavioral symptoms